Search clinical trials for: Imatinib and PTK/ZK222584

Total 2344 results

SCRI Development Innovations, LLC
Novartis

Completed

Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors

Solid Tumors | Refractory Malignancy

United States
M.D. Anderson Cancer Center
Novartis

Completed

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Agnogenic Myeloid Metaplasia

United States
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell Lung

China
Xiangya Hospital of Central South University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Gastrointestinal Stromal Tumors

China
Abbott Medical Devices

Active, not recruiting

LIFE-BTK Randomized Controlled Trial (LIFE-BTK)

Critical Limb Ischemia (CLI)

United States, Hong Kong, Australia, New Zealand, Singapore, Taiwan
Dana-Farber Cancer Institute
Novartis; Brigham and Women's Hospital

Completed

Protein Tyrosine Kinases (PTK) in Multiple Myeloma

Multiple Myeloma

United States
Scandinavian Sarcoma Group

Completed

Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)

Sarcoma

Sweden
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body

Chronic Myeloid Leukemia

China
Centre Leon Berard

Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)

Gastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene Mutation

France
Centre Hospitalier Universitaire de Nice

Completed

Drug-Eluting Balloon Angioplasty for the Treatment of Hemodialysis Vascular Access Stenosis (DEBAVAS) (B3AV)

Dysfunction of Hemodialysis Vascular Access (Fistula and Graft)

France
Sarit Assouline
Novartis

Recruiting

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | Chronic Myeloid Leukemia, BCR/ABL-Positive

Canada
M.D. Anderson Cancer Center
Novartis

Completed

Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST

Gastrointestinal Stromal Tumors

United States
Seoul St. Mary's Hospital
Novartis

Unknown

Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib (RE-NICE)

Chronic Myeloid Leukemia

Korea, Republic of
Dr. Jurjan Aman
Exvastat Ltd.; Simbec-Orion Group; KABS laboratories

Terminated

Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients (INVENT COVID)

Covid19 | Endothelial Dysfunction | Acute Respiratory Distress Syndrome | ARDS | Pulmonary Edema

Netherlands
University of Auckland, New Zealand
Leukaemia & Blood Cancer New Zealand

Active, not recruiting

KISS Study: Kinase Inhibition With Sprycel Start up (KISS)

Chronic Myeloid Leukemia

New Zealand
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Austria, Germany, United States, United Kingdom
Novartis Pharmaceuticals

Terminated

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENEST)

Myelogenous Leukemia

United States, Germany, Belgium, Italy, Spain, Korea, Republic of, Brazil, Japan, Australia, Czech Republic
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Metastatic Melanoma

Melanoma | Skin Neoplasms

United States
Novartis Pharmaceuticals

Completed

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors

United States, France, Belgium, Germany
M.D. Anderson Cancer Center
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myeloid, Chronic

United States
PETHEMA Foundation

Recruiting

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Acute Lymphoblastic Leukemia Ph Positive

Spain
Yonsei University

Completed

A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)

Fibromatosis

Korea, Republic of
St. Justine's Hospital

Terminated

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Plexiform Neurofibromas

Canada
Cttq
Ruijin Hospital

Unknown

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Chronic Myeloid Leukemia
Novartis

Completed

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

Chronic Myelogenous Leukemia in Chronic Phase
Novartis

Completed

Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen

Seasonal Allergic Rhinitis

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults

HIV Infections

United States, Switzerland
University of Helsinki
Bayer

Completed

PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib

Sarcoma

Finland
Institut Bergonié
Novartis

Terminated

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response (MIM)

Leukemia, Myeloid, Chronic-Phase

France
Asan Medical Center

Active, not recruiting

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Gastrointestinal Stromal Tumors

Korea, Republic of
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)

Chronic Myeloid Leukaemia

Italy
Centre Oscar Lambret
Novartis; National Cancer Institute, France

Terminated

Imatinib in Adult Patients With Metastatic Ocular Melanoma (O-Mel-Inib)

Melanoma

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Italy
Azienda Ospedaliera Universitaria Policlinico
Università Politecnica delle Marche

Unknown

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Systemic Sclerosis

Italy
Central European Leukemia Study Group

Unknown

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Chronic Myeloid Leukemia

Austria
University of Pittsburgh
Novartis

Completed

Effect of Antacids on Gleevec® in Healthy Volunteers

Healthy

United States
Samsung Medical Center

Active, not recruiting

Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

Advanced, Refractory Cancer

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Imatinib in Chordoma

Chordoma

Switzerland, Italy
Novartis Pharmaceuticals

Completed

A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors

Advanced Gastrointestinal Stromal Tumors

Italy
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck

Carcinoma, Adenoid Cystic | Cancer of the Head and Neck

France
Hospices Civils de Lyon

Unknown

Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.

Acute Lymphocytic Leukemia

France
National Institute of Allergy and Infectious Diseases...
IPPOX Foundation; EuroVacc Foundation; Global Solutions for Infectious Diseases

Withdrawn

Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults

HIV Infections
Novartis Pharmaceuticals

Completed

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate (Radix)

Progressive Gastrointestinal Stromal Tumor

Germany
Stanford University

Completed

Imatinib in Systemic Sclerosis

Scleroderma, Systemic

United States
Heidelberg University
Novartis

Completed

Study to Evaluate Imatinib in Desmoid Tumors

Desmoid Tumor | Aggressive Fibromatosis

Germany
Novartis Pharmaceuticals

Completed

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Life Threatening Diseases
UNICANCER

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Desmoid Tumor

France
University of Michigan Rogel Cancer Center

Terminated

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

Thyroid Cancer

United States
University Hospital, Bordeaux

Completed

Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia (STIM)

Myeloid Leukemia, Chronic

France
University Hospital, Bordeaux
Novartis; Ministry of Health, France

Completed

Efficacy and Safety of Imatinib in Scleroderma (SCLEROGLIVEC)

Scleroderma, Systemic | Scleroderma, Localized

France

Search clinical trials for: Imatinib and PTK/ZK222584

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations